​Sanofi (SNY) Strengthens Shareholder Returns Amid Robust 2025 Performance and Long-Term Growth Outlook

Sanofi (NASDAQ:SNY) is one of the best 52-week low blue-chip stocks to buy right now. On January 29, Sanofi SA (NASDAQ:SNY) reiterated plans to conduct a €1 billion share buyback in 2026. The buyback push comes as the company delivered a strong Q4 2025.

Sanofi posted strong fourth-quarter results, driven by surging demand for its asthma drug Dupixent, which it co-developed with Regeneron (REGN). Adjusted earnings per share came in at €1.53, while revenue climbed to €11.3 billion, both topping analyst forecasts. Dupixent sales jumped 32.2% to €4.2 billion, helping to offset a 2.5% drop in vaccine revenue, which slipped to €2 billion. Despite the upbeat report, Sanofi’s shares edged lower amid broader market volatility.

According to Chief Executive Officer Paul Hudson, profitable growth is expected to continue for at least 5 years. The remarks come as management is under pressure to show that the company’s pipeline can replace Dupixent’s revenues. The management team has already ramped up investment in research and development to support the ambition.

Sanofi (NASDAQ:SNY) is a major French-based multinational pharmaceutical and healthcare company that discovers, develops, manufactures, and markets pharmaceuticals, vaccines, and consumer healthcare products globally. Operating in over 60 countries, it specializes in immunology, oncology, rare diseases, and infectious diseases.

While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Best Cheap Stocks to Buy for 2026 and 10 Stocks with Huge Growth Potential According to the Media.

Disclosure: None. This article is originally published at Insider Monkey.